exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087633 RNA Name: hsa-miR-122-5p RNA Type: miRNA Chromosome: chr18 Starnd: + Coordinate: Start Site(bp): 58451088 End Site(bp): 58451109 External Links: hsa-miR-122-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand MSI2 chr17 57255851 57684689 + FAM102A chr9 127940582 127980989 - NAGK chr2 71064344 71079808 + SPRED2 chr2 65310851 65432637 - HGSNAT chr8 43140464 43202855 + PPDPF chr20 63520765 63522206 + SH3GL1 chr19 4360370 4400547 - SETD1A chr16 30957754 30984664 + PEA15 chr1 160205337 160215376 + C19orf54 chr19 40740856 40751553 - PIP4K2A chr10 22534854 22714578 - RPRD1B chr20 38033725 38127780 + CACNG4 chr17 66964707 67033398 + SOX11 chr2 5692384 5701385 + IGFBP5 chr2 216672105 216695549 - RAB1B chr11 66268590 66277492 + CSRP1 chr1 201483530 201509456 - VTI1A chr10 112446998 112818744 + ZNF3 chr7 100064033 100082548 - NHLRC3 chr13 39038306 39050109 + ZNF614 chr19 52012765 52030240 - NDOR1 chr9 137205685 137217009 + ALDOA chr16 30064164 30070457 + GRK3 chr22 25564675 25729294 + C19orf47 chr19 40319536 40348527 - SLC9A1 chr1 27098809 27166981 - STK4 chr20 44966479 45080021 + IER2 chr19 13150411 13154911 + PRR12 chr19 49591182 49626439 + KRT7 chr12 52232520 52252186 + miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC021092.1 chr19 44103007 44113183 - AC103702.1 chr17 48579630 48582259 - AL358472.3 chr1 153966516 153966930 + AL645465.1 chr1 244375100 244409592 - DSCAM-AS1 chr21 40383083 40385358 + NEAT1 chr11 65422774 65445540 + SNHG7 chr9 136721366 136728184 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.